FMI International

Foundation Medicine is a leading molecular information company dedicated to a transformation in cancer care, where treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling (CGP) assays, including FoundationOne CDx and FoundationOne Liquid CDx, which identify actionable alterations and provide treatment recommendations. As a subsidiary of Roche, Foundation Medicine collaborates with biopharmaceutical partners to advance precision medicine and accelerate drug development through its extensive genomic database and AI-enabled analytics. Its services are utilized globally by oncologists and researchers to match patients with targeted therapies, immunotherapies, and clinical trials.